glp-1 direct to consumer Lower drug prices are coming, but employers still need a sustainable cost strategy GLP-1 costs rise, but there
Description
doi: 10.2337/dc15-1736 21 SorliCHarashimaSITsoukasGMUngerJKarsblJDHansenTet al

Single-cell messenger RNA sequencing reveals rare intestinal cell types

Who Should Consider GLP-1 Treatment and Who Should Wait: A Provider Decision Framework GLP-1 medications may be appropriate for autoimmune patients with stable, well-controlled disease and elevated BMI or metabolic dysfunction

Obesity Management in adults: a review
While AOM tirzepatide has higher rates of prescriptions, its momentum slowed after the CVS formulary shift, just as AOM semaglutide shows potential renewed growth
